Q1 EPS Estimate for Lyell Immunopharma Boosted by Analyst

Lyell Immunopharma, Inc. (NASDAQ:LYEL) – Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for Lyell Immunopharma in a research note issued on Thursday, March 13th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.17) per share for the quarter, up from their previous estimate of ($0.20). HC Wainwright has a “Neutral” rating and a $1.00 price target on the stock. The consensus estimate for Lyell Immunopharma’s current full-year earnings is ($0.78) per share. HC Wainwright also issued estimates for Lyell Immunopharma’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.73) EPS.

Lyell Immunopharma Stock Down 11.7 %

NASDAQ LYEL opened at $0.52 on Monday. The company has a market cap of $152.66 million, a PE ratio of -0.65 and a beta of -0.41. Lyell Immunopharma has a 52 week low of $0.51 and a 52 week high of $3.15. The firm’s 50-day simple moving average is $0.62 and its two-hundred day simple moving average is $0.90.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The firm had revenue of $0.01 million for the quarter.

Institutional Trading of Lyell Immunopharma

A number of institutional investors have recently modified their holdings of LYEL. Decheng Capital LLC purchased a new position in Lyell Immunopharma in the 4th quarter valued at approximately $7,622,000. Foresite Capital Management V LLC purchased a new position in shares of Lyell Immunopharma in the fourth quarter valued at $5,205,000. venBio Partners LLC bought a new stake in shares of Lyell Immunopharma during the 4th quarter valued at $4,545,000. Renaissance Technologies LLC lifted its holdings in Lyell Immunopharma by 716.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,612,146 shares of the company’s stock worth $1,032,000 after purchasing an additional 1,414,746 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Lyell Immunopharma during the 4th quarter worth about $887,000. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.